BCTX · BriaCell Therapeutics Corp
United States · RS rating 30 · As of 2026-10-14
| Price | 3.69 USD |
|---|---|
| 1-day change | -0.5% |
| RS rating (overall / 1M / 3M / 12M) | 30 / 85 / 46 / 9 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 27 / 15 / 39 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +40.7% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +73.2% |
| Market cap (USD) | $27.0M |